Amendments To The Claims

1-6. (canceled)

7. (previously presented) A compound selected from the following formulae (C1) to (C11) and (C13)-(C20) or a pharmaceutically acceptable salt thereof:

C1)



C2)



C3)



C4)



C5)



C6)



C7)



C8)



C9)



C10)



C11)



C13)



C14)



C-15)



C16)



C17)



C18)



C19)



Page 4 of 13

C20)



8. (previously presented) A compound represented by the structural formula AA



(AA)

or a pharmaceutically acceptable salt thereof.

9. (previously presented) A compound selected from the group consisting of:



,



,



,



,



,



,



,











Page 7 of 13



or a pharmaceutically acceptable salt thereof.

10. (canceled)

11. (currently amended) A compound according to claim 36 wherein ZFP includes a carboxyl group ~~funcionalized~~ functionalized as a N,N-diethylglycolamido ester, or morpholinylethyl ester.

12. (previously presented) The salt derivative of the compound of claim 36 wherein the salt is sodium or potassium.

13. (previously presented) A pharmaceutical formulation comprising the compound of claim 36 either with a pharmaceutically acceptable carrier or diluent.

14-17. (canceled)

18. (currently amended) A method of treating a mammal ~~to prevent or alleviate the pathologiecal effects of Acne, Actinic keratosis, Insufficient sebum secretion,~~ for Osteoporosis or ~~, Insufficient dermal firmness, Insufficient dermal hydration,~~ Psoriasis~~, Scleroderma, Skin cancer, Skin cell damage from, Mustard vesicants, Wrinkles or Seborrheic dermatitis;~~ wherein the method comprises administering a pharmaceutically effective amount of at least one compound according to claim 36.

19. (original) The method of claim 18 for the treatment of psoriasis.

20. (original) The method of claim 18 for the treatment of osteoporosis.

21-35. (canceled)

36. (previously presented) A compound represented by a formula below:



wherein

R and R' are independently C_1-C_5 alkyl, or together R and R' form a saturated carbocyclic ring having from 3 to 8 carbon atoms;

RP_3 is hydrogen or C_1-C_5 alkyl;

(L_{P2}) is



and

where m is 0, 1, or 2,

Z_P is a branched C_3-C_5 alkyl;

Z_{FB} is attached to the 5 or 6 position on the benzofuranyl ring and selected from:

-CO_2H

-CO_2(C_1-C_5 alkyl),

-C(O)NMe_2,

-CO_2(C_1-C_5 alkyl)-NH_2,

-C(O)NH-CH_2-C(O)OH,

-C(O)NH-CH_2-C(O)OMe,

-C(O)NH-CH_2-C(O)OEt,

-C(O)NH-CH_2-C(O)OiPr,

-C(O)NH-CH_2-C(O)OtBu,

-C(O)NH-CH(Me)-C(O)OH,

-C(O)NH-CH(Me)-C(O)OMe,

-C(O)NH-CH(Me)-C(O)OEt,
-C(O)NH-CH(Me)-C(O)iPr,
-C(O)NH-CH(Me)-C(O)tBu,
-C(O)NH-CH(Et)-C(O)OH,
-C(O)NH-C(Me)$_2$-C(O)OH,
-C(O)NH-C(Me)$_2$-C(O)OMe,
-C(O)NH-C(Me)$_2$-C(O)OEt,
-C(O)NH-C(Me)$_2$-C(O)iPr,
-C(O)NH-C(Me)$_2$-C(O)tBu,
-C(O)NH-CMe(Et)-C(O)OH,
-C(O)NMe-CH$_2$-C(O)OH,
-C(O)NMe-CH$_2$-C(O)OMe,
-C(O)NMe-CH$_2$-C(O)OEt,
-C(O)NMe-CH$_2$-C(O)OiPr,
-C(O)NMe-CH$_2$-C(O)tBu,
-C(O)NMe-CH(Me)-C(O)OH,
C(O)-NH-5-tetrazolyl,
-O-SO$_2$-C$_1$-C$_5$ alkyl),
-SO$_2$(C$_1$-C$_5$ alkyl),
CH$_2$S(O)$_2$Me,
CH$_2$S(O)$_2$Et, and
CH$_2$S(O)$_2$iPr,

and a pharmaceutically acceptable salt thereof.

37. (previously presented) A compound represented by a formula:



and pharmaceutically acceptable salts thereof.

38. (previously presented) A compound represented by a formula:



and pharmaceutically acceptable salts thereof.

39. (withdrawn, currently amended) A method of treating a mammal or alleviating the pathological effects of psoriasis~~, scleroderma, seborrheic dermatitis or skin cancer or, a mammal~~ in need thereof comprising administered a pharmaceutically effective amount of a compound of Claim 37, or a pharmaceutically acceptable salt thereof.

40. (previously presented) A compound represented by a formula:



and pharmaceutically acceptable salts thereof.

41. (previously presented) A pharmaceutical formulation comprising the compound of claim 37 with a pharmaceutically acceptable carrier or diluent.

42. (previously presented) A pharmaceutical formulation comprising the compound of claim 38 with a pharmaceutically acceptable carrier or diluent.

43. (previously presented) A pharmaceutical formulation comprising the compound of claim 40 with a pharmaceutically acceptable carrier or diluent.